| Gleevec/Glivec |
All Financial Data in US $ (mln) |
| Word Search (Top 10 - by date) |
Novartis Drug Tasigna® Approved in Switzerland After Fast-track Review for Treatment of Patients With Newly Diagnosed Ph+ CML
Novartis
(August 27, 2010)
|
Synta Announces First Patient Treated In Clinical Trial of STA-9090 In Combination With Docetaxel In Solid Tumors
Synta Pharmaceuticals
(August 24, 2010)
|
CytRx Reports 2010 Second Quarter Financial Results
CytRx
(August 09, 2010)
|
Synta Pharmaceuticals Reports Second-Quarter 2010 Financial Results and Clinical Update
Synta Pharmaceuticals
(August 09, 2010)
|
Synta Announces STA-9090 Results Published In Journal "Blood" Demonstrating Potent In Vitro and In Vivo Activity In AML
Synta Pharmaceuticals
(July 27, 2010)
|
Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data and Double-Digit EPS Growth
Bristol-Myers Squibb
(July 22, 2010)
|
CytRx Announces Substantial Progress with Its Bafetinib Clinical Trials Program
CytRx
(July 19, 2010)
|
Novartis Delivers Strong Financial Performance in Second Quarter, Underpinned by Increased Momentum in Innovation
Novartis
(July 15, 2010)
|
SPRYCEL® (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase
Otsuka Pharmaceutical
(July 09, 2010)
|
SPRYCEL® (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase
Bristol-Myers Squibb
(July 09, 2010)
|
|
|
|
|
EvaluatePharma® - the premier source for pharma and biotech analysis.
Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.
|
| Summary Product Name Information |
|
|
| Product Sales Summary 2007/08 |
|
Annual Sales WW - Sales
|
Growth per Year (%)
|
|
Rank1 |
Generic Name
|
Therapeutic Subcategory
|
2007 |
2008
|
2008 |
| Gleevec/Glivec2 |
|
|
|
3,050 |
3,670 |
|
+20% |
|
|
Note: Shaded Cells3 |
|
|
More Product Information for EvaluatePharma® subscribersSubscribers see:
- Sales (historic and forecast to 2016 where available) listed by the reporting company or companies, including royalty, license and JV revenue where applicable
- Details of all events impacting the product
- Detailed product information, including sales forecasts listed by the reporting company or companies, indications (approved and in trial)
|
Register to access more FREE content:
- 2009 Product Sales analysis
- Download analysis into Excel
- Search 2 yrs of company press releases
|
|
|
|